Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, and squamous cell carcinoma antigen in the detection of cervical cancers

Zhonghua Yi Xue Za Zhi (Taipei). 1992 Jul;50(1):7-13.

Abstract

Cervical cancer is a predomiannt gynecologic neoplasia in Taiwan. The associations of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and squamous cell carcinoma antigen (SCC-Ag) for detection of cervical cancers with type of cancer, clinical stage and lymph node metastasis were studied. Serum samples were collected from 395 patients with cervical cancers (61 CIN3, 334 squamous cell carcinoma, 18 adenocarcinoma), 72 patients with benign gynecologic diseases and 115 healthy controls. The sensitivities of CEA, TPA, and SCC-Ag were 15.2%, 33.6%, and 49.3%. The specificities were 89.3%, 96.2%, and 95.1%, respectively. The positive rate of CEA was found significantly higher among patients with adenocarcinoma than those with squamous cell carcinoma. The positive rate of CEA and SCC-Ag increased with advance of the clinical stages. There was no significant difference in the rate of each tumor marker between patients with lymph node metastasis and those without metastasis. The positive rate obtained by SCC-Ag alone was comparable to those by the combinations of two or three antigens. The result of the present study indicates that SCC-Ag is the most useful tumor marker in the detection of cervical cancers.

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / immunology
  • Antigens, Neoplasm / analysis*
  • Biomarkers, Tumor / analysis*
  • Carcinoembryonic Antigen / analysis*
  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / immunology
  • Female
  • Humans
  • Peptides / analysis*
  • Serpins*
  • Tissue Polypeptide Antigen
  • Uterine Cervical Neoplasms / diagnosis*
  • Uterine Cervical Neoplasms / immunology

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Peptides
  • Serpins
  • Tissue Polypeptide Antigen
  • squamous cell carcinoma-related antigen